secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023254
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q3 net loss $14.8M; pauses ENLIGHTEN II enrollment for in-house mfg
--------------------------------------------------------------------------------

- Net loss of $14.8M for Q3 2022, compared to $11.1M in Q3 2021.
- Cash and equivalents $109.6M; expected to fund operations through mid-2024.
- ENLIGHTEN I Phase 3 trial on track for enrollment completion mid-2023; ENLIGHTEN II paused, resuming Q3 2023.
- BEACON Phase 2 trial of LYR-220 advanced to randomized stage; initial data submitted for 2023 meeting.
- R&D expenses rose to $10.0M from $7.1M year-over-year due to clinical trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/0000950170-22-023254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/lyra-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer